Vicent, LourdesEsteban Fernández, AlbertoGómez Bueno, ManuelJuan Bagudá, Javier deDíez Villanueva, PabloIniesta, Ángel ManuelAyesta, AnaGonzález Saldivar, HugoRojas González, AntonioBover Freire, RamónIglesias del Valle, DiegoGarcía Aguado, MarcosPerea Egido, Jesus ÁngelMartínez Sellés Oliveria Soares, Manuel2019-05-122019-05-122019Vicent, L., Esteban-Fernández, A., Gómez-Bueno, M., De-Juan, J., Díez-Villanueva, P., Iniesta, Á. M., ... & Iglesias, D. (2019). Sacubitril/valsartan in daily clinical practice: data from a prospective registry. Journal of Cardiovascular Pharmacology, 73(2), 118-124. https://doi.org/10.1097/FJC.00000000000006410160-24461533-4023http://hdl.handle.net/11268/7890Sacubitril/valsartan (SV) is a new therapy in heart failure with reduced ejection fraction. Our aim was to determine the efficacy and safety of this drug daily clinical practice. We performed a multicenter registry in 10 hospitals. All patients who started SV from October 2016 to March 2017 on an outpatient basis were included. A total of 427 patients started treatment with SV. Mean follow-up was 7.0 ± 0.1 months. Forty-nine patients (11.5%) discontinued SV, and 12 (2.8%) died. SV discontinuation was associated with higher cardiovascular (hazard ratio 13.22, 95% confidence interval, 6.71-15.73, P < 0.001) and all-cause mortality (hazard ratio 13.51, 95% confidence interval 3.22-56.13, P < 0.001). Symptomatic hypotension occurred in 71 patients (16.6%). Baseline N-terminal pro-B-type natriuretic peptide levels, functional class, and left ventricular ejection fraction improved at the end of follow-up in patients who continued with SV (all P values ≤0.001). This improvement was not significant in patients with SV discontinuation. SV has a good tolerability in patients from daily clinical practice. SV withdrawal in patients with heart failure and reduced ejection fraction was independently associated with increased all-cause mortality. Patients who continued with SV presented an improvement in functional class left ventricular ejection fraction and N-terminal pro-B-type natriuretic peptide levels.engjournal article10.1097/FJC.0000000000000641restricted accessInsuficiencia cardíacaTerapéuticaEnfermedad cardiovascularTratamiento médicoMedicamento